{"id":"W4394595366","doi":"10.1016/j.eururo.2024.03.029","title":"Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","year":2024,"lang":"en","type":"editorial","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Oncology; Internal medicine; Bladder cancer; Urology; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002464624,0.0006195978,0.0009382576,0.0003786688,0.00005792129,0.00004440428,0.0002077873,0.0005187386,0.0005123959],"category_scores_gemma":[0.000299776,0.0005370908,0.0001443952,0.0002621137,0.0001913846,0.00005589882,0.0001970047,0.001539133,0.000445848],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002734324,"about_ca_system_score_gemma":0.0008051297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006292021,"about_ca_topic_score_gemma":0.0006899759,"domain_scores_codex":[0.9969642,0.0003141821,0.0005867581,0.00108932,0.0004105009,0.0006350371],"domain_scores_gemma":[0.9987555,0.0002465853,0.0001493858,0.0005161696,0.0001083744,0.0002239696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004735367,0.0001619829,0.0006884439,0.000433602,0.0004233802,0.004902485,0.000663752,0.00001235867,0.0001375845,0.00003346465,0.9680675,0.01974013],"study_design_scores_gemma":[0.009218981,0.001574873,0.001669239,0.0002901691,0.0007032055,0.00004942494,0.00002381884,0.00002552145,0.0000414761,0.00006672473,0.9859418,0.0003948002],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.01350727,0.02227828,0.000005370146,0.002037496,0.8617376,0.001511404,0.001135965,0.0004594317,0.09732719],"genre_scores_gemma":[0.1625787,0.009558952,0.00008528161,0.001571827,0.7973751,0.000229654,0.001088967,0.0006986614,0.0268129],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.1490714,"threshold_uncertainty_score":0.9997081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01013489064885537,"score_gpt":0.2911570393851965,"score_spread":0.2810221487363411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}